What off-label prescribing means for an approved peptide medicine

A medicine can be FDA-approved for one condition while a clinician considers it for another. FDA calls that proposed use “off label.” The product retains its approved manufacturing and labeling status, but FDA has not approved the new use. This is different from buying a research-only substance or receiving a compounded preparation that itself has not been FDA-approved. Ask the clinician to name the product and the approved indication before discussing the proposed one. FDA: Understanding off-label use FDA: Compounding and the FDA Q&A

Find out whether controlled human studies, professional guidance, or only case reports support the proposal. Ask whether people like you were studied and whether the outcome is meaningful. FDA’s patient page specifically suggests asking what scientific studies are available and why the clinician believes the drug could help. Mechanistic plausibility alone cannot establish that the off-label use is effective or safe for your condition. FDA: Understanding off-label use

Contraindications, warnings, interactions, and population cautions still matter when the product is used off label. The risk-benefit balance can differ because the expected benefit is less certain or the patient group is different from the approved trial population. FDA’s labeling FAQ explains the role of professional and patient labeling. Discuss any risk not directly studied in the proposed use, plus monitoring and a reason to stop. FDA: Labeling FAQ for prescription medicines

Ask what approved treatments are available for your condition, why an off-label option is being considered, what follow-up will measure, and who will handle adverse effects. Shared decision-making includes your priorities and willingness to accept uncertainty. Avoid treating the phrase “doctors can prescribe it” as evidence of benefit. The relevant question is whether the specific use makes sense for your clinical circumstances. AHRQ: SHARE approach

Ask the clinician to separate evidence for the approved use from evidence for the proposed off-label use. A product might have strong manufacturing review and a well-described general safety profile, while the benefit for the new condition remains uncertain. The clinician should explain whether human studies directly tested the new indication and whether the patient resembles participants. This distinction is more informative than simply labeling the idea “experimental” or “common practice.” FDA: Understanding off-label use

New symptoms, another diagnosis, pregnancy, or emerging trial results can change the rationale for an off-label prescription. Agree on a review point, meaningful outcome, and stop rule. If an approved treatment for the condition becomes available, ask whether that changes the comparison. AHRQ’s shared-decision framework supports revisiting benefits, harms, and preferences as the evidence and patient circumstances change. AHRQ: SHARE approach